About Aurobindo Pharma
Aurobindo Pharma is a company based in Hyderabad (India) founded in 1986 by P V Ramprasad Reddy and K Nityananda Reddy. The company has 40,750 employees as of March 31, 2024. Aurobindo Pharma has completed 8 acquisitions, including Advent Pharma, GLS Pharma and Generis Farmaceutica. Aurobindo Pharma offers products and services including APIs, Biosimilars, and Speciality Products. Aurobindo Pharma operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Asymchem, among others.
- Headquarter Hyderabad, India
- Employees 40750 as on 31 Mar, 2024
- Founders P V Ramprasad Reddy, K Nityananda Reddy
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aurobindo Pharma Ltd
-
Annual Revenue
$3.67 B (USD)9.32as on Mar 31, 2024
-
Net Profit
$407.24 M (USD)9.86as on Mar 31, 2024
-
EBITDA
$753.39 M (USD)12.89as on Mar 31, 2024
-
Latest Funding Round
Not available
-
Investors
Gates Foundation
& 1 more
-
Employee Count
40750
as on Mar 31, 2024
-
Investments & Acquisitions
Advent Pharma
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aurobindo Pharma
Aurobindo Pharma is a publicly listed company on the NSE with ticker symbol AUROPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aurobindo Pharma
Aurobindo Pharma offers a comprehensive portfolio of products and services, including APIs, Biosimilars, and Speciality Products.
Raw materials used in drug manufacturing for global markets.
Generic biologics targeting oncology and immunology therapies.
Advanced drugs for specific therapeutic needs worldwide.
People of Aurobindo Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Aurobindo Pharma
Investors in Aurobindo Pharma
Aurobindo Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation and Templeton Private Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Aurobindo Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aurobindo Pharma
Aurobindo Pharma has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Advent Pharma, GLS Pharma and Generis Farmaceutica.
Investment portfolio details for Aurobindo Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bio-conjugate technologies for bacterial vaccines and conjugates are developed.
|
Locked | Locked | 2008 | Locked | |
|
Generic liquid and solid formulations are manufactured for pharmaceuticals.
|
Locked | Locked | 2005 | Locked | |
|
Oncology APIs and anti-cancer products are manufactured.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Aurobindo Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aurobindo Pharma
Detailed financials for Aurobindo Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aurobindo Pharma Comparisons
Peer comparison for Aurobindo Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aurobindo Pharma
Aurobindo Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Asymchem, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of Aurobindo Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aurobindo Pharma
Complete news archive for Aurobindo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurobindo Pharma
Aurobindo Pharma was founded in 1986 and raised its 1st funding round 13 years after it was founded.
Aurobindo Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Sanjay Chaturvedi is the current CEO of Aurobindo Pharma.
As of Mar 31, 2024, the latest employee count at Aurobindo Pharma is 40,750.
Annual revenue of Aurobindo Pharma is $3.67B as on Mar 31, 2024.
Aurobindo Pharma was founded in 1986 in Hyderabad, India, and operates within the pharmaceutical sector. Generic drugs and biocatalytic solutions are developed and manufactured by the company, with a focus on active pharmaceutical ingredients and formulations. Operations are conducted globally, serving markets in over 150 countries through exports and partnerships. Leadership is provided by co-founders P V Ramprasad Reddy and K Nityananda Reddy, alongside CEO Sanjay Chaturvedi.
Aurobindo Pharma's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Aurobindo Pharma offers APIs, Biosimilars, and Speciality Products.
Yes, Aurobindo Pharma is publicly traded on NSE under the ticker symbol AUROPHARMA.
Aurobindo Pharma has made 8 acquisitions, including Advent Pharma, GLS Pharma, and Generis Farmaceutica.
Aurobindo Pharma has 2 investors. Key investors include Gates Foundation, and Templeton Private Equity Partners.
The ticker symbol of Aurobindo Pharma is AUROPHARMA on NSE.